About Oragenics
Oragenics is a publicly listed company based in Tampa (United States) founded in 1996. Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health. The company has 3 employees. Its chief executive, as recorded, is Alan Joslyn. Oragenics offers products and services including Vaccine Program, Pipeline, and Science and Technology. Its focus areas include Life Sciences, Nutraceuticals Tech, Functional Foods and Beverages and Probiotics. Its legal entity is Oragenics, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Oragenics was founded in 1996 and is based in Tampa, United States. Operations focus on the biotechnology sector, where treatments for infectious diseases and oral mucositis are developed, complemented by probiotics aimed at oral health maintenance. The lead candidate, AG013, is formulated as a live biotherapeutic oral rinse that delivers Trefoil Factor 1 to mucosal tissues in the oral cavity. Leadership is provided by CEO and President Alan Joslyn.
- Headquarters Tampa, United States
- Employees 3
- Stage Public
- SectorsHealthcare
- Website oragenics.com
- Social LinkedIn X Facebook
- Legal Name Oragenics Inc.
- Net Profit-$9.84 M (USD)6.86as on Dec 31, 2025
- EBITDA-$9.36 M (USD)11.33as on Dec 31, 2025
- Latest Funding Round$850K (USD), Post-IPO
Aug 2023
- InvestorsHHS
& 3 more
- Employee Count3
Products & Services of Oragenics
Oragenics offers a comprehensive portfolio of products and services, including Vaccine Program, Pipeline, and Science and Technology.
Develops vaccines targeting brain-related conditions and unmet needs.
Manages research pipelines for pharmaceutical innovations.
Provides tools for brain-related drug advancement and publications.
Funding Insights of Oragenics
- Total Rounds 17
- Last Round Post-IPO — $850,000
- First Round $1M
(Feb 2008)
- Investors Count 4
Latest 10 of 17 funding rounds of Oragenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $850,000 | Post-IPO | – | – | – |
| Oct 2021 | $250,000 | Grant | – | – | |
| Aug 2021 | $256,654 | Grant | – | – | |
| Feb 2021 | $22M | Post-IPO | – | – | – |
| Apr 2018 | $1.8M | Post-IPO | – | – | – |
| Nov 2017 | $6.68M | Post-IPO | – | – | – |
| May 2017 | $1.3M | Post-IPO | – | – | – |
| Jul 2016 | $4.67M | Post-IPO | – | – | – |
| Oct 2013 | $9.9M | Post-IPO | – | – | |
| Aug 2012 | $2.54M | Post-IPO | – | – | – |
4 investors in total: 4 institutional.
Investors in Oragenics
Oragenics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Precigen and National Institute of General Medical Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Basic research is supported to advance medical sciences. | nigms.nih.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | 1998 | precigen.com | Germantown, United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Oragenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oragenics
8 people are tracked at Oragenics (2 in leadership, 6 in board & advisors); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Alan Joslyn | CEO & President | Leadership |
Janet Huffman | Chief Executive Officer | Leadership |
Charles L. Pope | Director | Board & advisors |
Robert Koski | Director | Board & advisors |
David Zarley | Scientific Advisor | Board & advisors |
Terrence Cochrane | Scientific Advisor | Board & advisors |
Timothy Cooke | Scientific Advisor | Board & advisors |
Alan W. Dunton | Director | Board & advisors |
Complete people profiles for Oragenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Oragenics
Oragenics is a publicly listed company on the AMEX with ticker symbol OGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Feb 2023
- Listed onLSE: 0A64
- Listed entityOragenics Inc.
- Exchange sectorHealth technology
- ISINUS6840236094
- Share price$0.45 (-0.16% on the day) · 2026-10-13
- Market capitalisation$2.0M
- EPS (diluted, trailing year)$-3.58
- Volume (last session)16,630
Financials of Oragenics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$9.8M | -$9.4M | |
| 2024 | -$10.6M | -$10.6M | |
| 2023 | -$20.7M | -$10.6M | |
| 2022 | -$14.3M | -$14.5M | |
| 2021 | $86,990 | -$15.7M | -$15.7M |
Detailed financial statements for Oragenics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Oragenics
4 dated milestones of Oragenics across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Oragenics is founded.
- Funding First funding round of $1.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $850K.
Competitors of Oragenics
Oragenics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Oragenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Oragenics
The website of Oragenics (oragenics.com) receives about 3.8K visits a month.
- Monthly visits3.8K
▼ 35% vs previous month
Top companies in Nutraceutical & Food-as-Medicine Platforms
3 companies that operate in the same segment as Oragenics (Nutraceutical & Food-as-Medicine Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapies for metabolic health in chronic disease patients are provided. | 2014 | San Francisco, California, United States | USD 401.78 M | 910 | ||
Personalized gut health solutions are provided by ZOE. | 2017 | New Castle, Pennsylvania, United States | USD 15 M | |||
Machine learning-based bioinformatics solutions for health insights are provided. | 2016 | Los Alamos, New Mexico, United States | USD 301.57 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oragenics
Complete news archive for Oragenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oragenics
Oragenics was founded in 1996 and raised its 1st funding round 12 years after it was founded.
Oragenics is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Alan Joslyn is the CEO of Oragenics, as recorded in our data.
Oragenics has 3 employees.
Oragenics was founded in 1996 and is based in Tampa, United States. Operations focus on the biotechnology sector, where treatments for infectious diseases and oral mucositis are developed, complemented by probiotics aimed at oral health maintenance. The lead candidate, AG013, is formulated as a live biotherapeutic oral rinse that delivers Trefoil Factor 1 to mucosal tissues in the oral cavity. Leadership is provided by CEO and President Alan Joslyn.
Oragenics offers Vaccine Program, Pipeline, and Science and Technology.
Yes, Oragenics is publicly traded on AMEX under the ticker symbol OGEN.
Oragenics has 4 investors. Key investors include HHS, Precigen, National Institute of General Medical Sciences, and National Science Foundation.
Oragenics operates through Oragenics, Inc..